In 2014, MPP entered into a voluntary licence agreement with ViiV Healthcare for dolutegravir (DTG), WHO's recommended HIV treatment. Since then, generic DTG-based treatments supplied through MPP's licences have reached more than 5 million people living with HIV across nearly 100 low- and middle-income countries.
In this roundtable leading up to the 23rd International AIDS Conference, MPP brings together some of the key players that made this scale up possible. The panel, moderated by MPP's Board Chair Marie-Paule Kieny, will discuss how the MPP model has changed the HIV landscape, and reflect on how the lessons learned can be applied to the fight against COVID-19.
Full programme here: http://ow.ly/W2P430qR8fi
We hope you will be able to join us for this exciting roundtable discussion.